Abstract
Background NUC-3373 is a novel thymidylate synthase (TS) inhibitor designed to directly deliver the active anti-cancer metabolite fluorodeoxyuridine-monophosphate (FUDR-MP or FdUMP) intracellularly. In addition to being a potent TS inhibitor, NUC-3373 has also been shown to cause DNA damage and promote the release of damage-associated molecular patterns. These diverse mechanisms position NUC-3373 as a potentially effective combination partner for several other anti-cancer agents.
Methods NuTide:303 is a Phase Ib/II open label, multi-arm, parallel cohort dose-finding and expansion study designed to evaluate optimal combination partners for NUC-3373. Module 1 planned to enroll up to 12 evaluable patients with advanced/metastatic solid tumors to determine the recommended dose for NUC-3373 in combination with leucovorin (LV) and pembrolizumab. Module 2 planned to enroll approximately 6-12 evaluable patients with advanced/metastatic non-small cell lung cancer (of any histology) or pleural mesothelioma to determine the recommended dose for NUC-3373 in combination with LV and docetaxel. A 3+3 dose escalation design was used in both modules, with safety parameters continually assessed and tumor assessments conducted at screening and every 8 weeks from C1D1 until progression.
Results Thirteen patients were enrolled in Module 1, with 9 evaluable for response. No DLTs were observed in these heavily pre-treated PD-(L)1 experienced patients with a variety of different tumor types. Four patients remained on treatment for >3 months and 3 patients were ongoing at the time of data cut-off. An objective response rate of 22% and a disease control rate of 67% were reported. NUC-3373 + LV + pembrolizumab was well tolerated, the most common treatment-related adverse events (AEs) were nausea, vomiting, and diarrhea and the majority of events were Grade 1 (100%) or 2 (85%). Four patients were enrolled in Module 2, with 3 evaluable for response. Two patients treated at the first dose level achieved stable disease and completed >6 months of treatment The most common treatment-related AEs were fatigue (n=4) and diarrhea (n=3) and the majority of events were Grade 1 (100%) or 2 (100%).
Conclusions Preliminary results from Module 1 show signals of anti-cancer activity and tolerability, providing support for further exploration of this combination in the Phase II part of the study. Preliminary results from Module 2 suggest that the probability of being able to escalate to typical efficacious doses of docetaxel used in combination is low due to overlapping toxicity. Further modifications to include the use of a different taxane in this combination are currently being considered.
Competing Interest Statement
GM has performed consulting and advisory roles at Roche, Boehringer Ingelheim, Mina therapeutics, D2G, BMS, MSD, and AstraZeneca, participated in speakers bureaus for Roche, BMS, MSD, AstraZeneca, Servier, and Bayer, and received research funding from BMS, MSD, AstraZeneca, and Plexxikon. JS owns stock in Epsilogen Ltd and Avacta Ltd, holds board membership at Apobec Discovery Ltd, has performed advisory roles at Apobec Discovery Ltd, Avacta Ltd, AstraZeneca, BioNTech, BMS and Roche, has received assistance with attendance at international meetings from Starpharma and MSD, and has received reimbursement for recruitment to clinical trials from Achilles, Gilead, GSK, IO Biotech, MSD, Roche, RS Oncology, and Starpharma. RW has performed consultancy and advisory roles at Alcimed, Amphista Therapeutics, BMS, Boehringer Ingelheim, CV6 Therapeutics, NuCana, RIN Institute and Takeda, has received assistance with attendance at international meetings from NuCana and Takeda, and has received honoraria for educational meetings from Bayer, Merckgroup, Pierre Fabrier, Servier and Takeda. DJH is a part time employee of NuCana and non executive director of ILC Therapeutics. EO and JB are full-time employees of NuCana. FT has performed consulting and advisory roles at CytomX, Kite, Gilead, Scenic Biotech, Immatics, T Knife Therapeutics, FStar, Grey Wolf Therapeutics, and AstraZeneca.
Clinical Trial
EudraCT 2022-000722-14; NCT05714553
Funding Statement
This study was funded by NuCana plc
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
West Midlands - Coventry & Warwickshire Research Ethics Committee gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Disclosure: GM has performed consulting and advisory roles at Roche, Boehringer Ingelheim, Mina therapeutics, D2G, BMS, MSD, and AstraZeneca; has participated in speakers’ bureaus for Roche, BMS, MSD, AstraZeneca, Servier, and Bayer; and has received research funding from BMS, MSD, AstraZeneca, and Plexxikon. JS owns stock in Epsilogen Ltd (co-founder) and Avacta Ltd; holds board membership at Apobec Discovery Ltd; has performed advisory roles at Apobec Discovery Ltd, Avacta Ltd, AstraZeneca, BioNTech, BMS and Roche; has received assistance with attendance at international meetings from Starpharma and MSD; and has received reimbursement for recruitment to clinical trials from Achilles, Gilead, GSK, IO Biotech, MSD, Roche, RS Oncology, and Starpharma. RW has performed consultancy and advisory roles at Alcimed, Amphista Therapeutics, BMS, Boehringer Ingelheim, CV6 Therapeutics, NuCana, RIN Institute and Takeda; has received assistance with attendance at international meetings from NuCana and Takeda; and has received honoraria for educational meetings from Bayer, Merckgroup, Pierre Fabrier, Servier and Takeda. DJH is a part-time employee of NuCana. EO and JB are full-time employees of NuCana. FT has performed consulting and advisory roles at CytomX, Kite, Gilead, Scenic Biotech, Immatics, T-Knife Therapeutics, F-Star, Grey Wolf Therapeutics, and AstraZeneca.
Funding: This study was funded by NuCana plc.
Data Availability
All data produced in the present study are contained in the manuscript and supplementary data
